DOCSLIB.ORG

GCP Challenges for 2008 and Beyond

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GCP Challenges for 2008 and Beyond COMMENTARY GCP Challenges for 2008 and Beyond Matthew Whalen, Brian Edwards, John Mather INTRODUCTION Here, Good Clinical Practice(s) (GCPs) are viewed in both their current and potential state as central to the social enterprise called clinical re- search. In that light, this piece reflects the seminal definition from EU Directive 2001/20/EC, article 1, clause 2: “Good clinical practice is a set of internationally recognized ethical and scientific quality requirements which must be observed for designing, conducting, recording, and reporting clinical trials that involve the participation of human subjects.” Featuring “ethical and scientific quality requirements” and the phrasing of “designing, conducting…” is significant. Together, they emphasize the essential need to understand the nature of quality and processes - in the most far-reaching sense of each - in order to make clinical research viable. Addressing the challenges facing GCPs is closely aligned with refram- ing and reforming the entire system of research and development of bio- medical therapeutics. As such, it is critical to view GCPs in a larger con- text, inclusive of, but not limited to, regulatory reform. CURRENT CHALLENGES Professionals working in the GCP environment are facing important challenges - equally familiar to our other GXP colleagues, including de- velopment of appropriately educated and trained GCP professionals themselves to support GCP development. However, there does appear to be intensified urgency due to the im- mediate relevancy of GCPs for the world's patients and research volun- teers, reinforced by on-going media and political attention as well as pressure on development pipelines. Four such challenges are among the most far-reaching in terms of im- plications for reform: • Globalization - embracing both developing and re-developing coun- tries opening up a wealth of new opportunities as the marketplace determines where research can be performed to achieve the best value while maintaining acceptable local and international ethical standards. 8 Journal of GXP Compliance Matthew Whalen, Brian Edwards, John Mather • Innovation - the on-going and dramatic ones, corporations to small healthcare centers and pri- such as pharmacogenetics, and the uncertainties vate practices based on best evidence derived of novel biotechnology, such as stem cells and from safety practices in other safety-conscious nanotechnology, and their ethical and social sectors of society and ideally converted into ramifications. Guiding Principles • Resource Investments - significant scrutiny from • Information and knowledge management - in both within the life sciences sector and outside; particular, the inter-connectivity across the as well as pressures on reimbursement with a whole research endeavor and project stakehold- failing ROI (Return on Investment) once bio- ers and extrapolation into the marketplace medical therapies are marketed; and • Organizational learning and memory so that the • Trust - what may be unprecedented shakiness of system of the entire research enterprise learns confidence and increasing skepticism of the from mistakes world's publics in organizations and corporate • Internal and external management and monitor- infrastructure, in general, and the pharmaceuti- ing of audits of research sites and inter-organiza- cal sector, in particular. tional committees responsible for important as- As a result, not only international regulatory au- pects of trials, such as the IRBs/ERCs and thorities, but also the full-range of R&D stakehold- DMCs/DSMBs ers is under operational, public, and political pres- • Developmental structures supporting profes- sure to reform the system that delivers the lifecycle sionalization of the clinical research team in- of biomedical therapies while still maintaining ac- cluding formal education and certification stan- ceptable safety and ethical standards. dards, and When these big picture challenges are translated in • Better international implementation of the Insti- terms of GCPs, they may be reduced, if grossly, to a tutional Official, GMP Qualified Person, Quali- focus on “overseers,” such as regulators and monitors, fied Person for Pharmacovigilance, and Chief and “oversight-related structures of the clinical re- Safety Officer roles as key organizational over- search process,” such as regulatory and accreditation seers of research and marketing of therapies agencies. What are the roles, responsibilities, and who have been allocated legal accountabilities processes to improve the adequacy and related orga- for overlapping parts of the system nizational and individual accountabilities? Renovation on this scale requires a certain funda- mental perspective: Seeing research systemically as There is a spectrum of reform potential: opposed to functional fragments and silos - both • Internationally harmonized regulations and within organizations and in the network of relations- guidance under-girding human subject protec- linking organizations. Diagrammatically, the empha- tions, that is, rational and culturally-appropriate sis is on the flow between and among the pieces, for implementation of the Declaration of Helsinki, example: World Health Organization (WHO) guidelines, • From a dynamic job description where respon- and other benchmark ethical statements sibilities include not only to and for whom, but • Widely-accessible and 'user-friendly' public com- with whom munications - ranging from public registries and • Through depiction of the human research pro- databases to media presentations popularizing re- tection program of an organization and the vari- search education - that support transparency and ety of supporting functions as well as outreaches public confidence, in the broadest sense, while • To a 'global' mapping of a project or program also keeping patients and subjects properly in- that, literally, reaches across the full-range of formed to maintain their interest and compliance stakeholders with treatment and research protocols This does not, however, lessen the importance of • Organizational safety culture, spanning nation individual accountability within the larger system. state and multi-lateral agencies through large Indeed, accountability is most effective and efficient January 2008 Volume 12 Number 2 9 COMMENTARY when maintained by each individual functioning grees of implementation of the spectrum of possible within collaborating teams founded on mutual inter- reforms. dependence with each looking out for the other. The While there is not a crisis in the traditional, full- environment is cross-disciplinary - and disciplined - blown sense, there is a slow burning brush fire ac- making it far more likely that any deliberate and celerating because the root causes of recurrent crises malevolent violations stand out in such a way that continue not to be fully investigated. Further, what inappropriate behavior is exposed promptly. Equally solutions have been suggested, have neither been important to strengthening accountability is the systematic in nature nor applied systemically. Sadly, blame-free dimension of this kind of environment there are those who complacently believe the drug when the actions are not deliberate nor malevolent - safety crises have been fully investigated, further ag- focusing on the insufficiency of process rather than gravating the situation. victimizing the individual. As a result, the root causes, including those of drug safety, have largely been ignored so that the BASIS FOR URGENCY threshold for declaring yet another new crisis is now What is generating the intensity of urgency for re- depressingly low. This further erodes long-term pub- form now is greater than that solely associated with lic confidence and is exacerbated by the inadequacy the safety of therapeutics products. Rather, it is one of societies to meet three challenges urgently requir- embracing processes, teams, and system of GXPs. ing a much more mature and robust system: The urgency, not surprisingly, is a cumulative effect • The presence of epidemics and pandemics, such of the aforementioned challenges and varying de- as avian influenza and multi-resistant bacteria Pharmaceutical Statistics 2008 Exploring controversial statistical issues in pharmaceutical development, QA/QC, and manufacturing March 18 & 19, 2008 • Westin Arlington Gateway • Arlington, VA In 2 days or less, you can experience... INNOVATION Participate in a 2-day, fast-paced conference format where you and the 13 Don’t miss H. Gregg Claycamp’s speakers can interact and mutually contribute to working through new and/or (Director, Division of Compliance Risk contentious statistical issues. Management and Surveillance, CDER, FDA) presentation on INCLUSION “Risk Assessment Learn and network by applying your own organization-specific statistical issues to ideas presented during the sessions and breakouts that will be in an ICH Q9 World” conducted using plain English. INSIGHT Explore the most pressing statistical issues usually discussed behind closed doors, including USP Chapter <111>, ICH Q9, sampling during 30 minute Brought to speaker sessions, 1-hour interactive discussion groups, networking breaks, you by: and a speaker roundtable luncheon. Sponsorship/Exhibit opportunities INTERACTION W Sales Manager Jamie Carpenter K Unique access to speakers hailing from the FDA USP and top industry 3 3 2 800-225-5469 x. 2725 giants, including: Amgen, Eli Lilly and Company, GlaxoSmithKline, Merck & 7 0 0 Co., Inc. TAP Pharmaceuticals, and many other cutting-edge
Load more

Recommended publications
  • NIHR CRN GCP Resources Document
    NIHR CRN GCP Resource A compilation of links to useful on-line GCP quality tools and resources NIHR CRN Good Clinical Practice Reference Resource Acknowledgements This GCP Resource has been produced by Dr Stuart McCully of Compliance Healthcheck Consulting UK Ltd (www.chcuk.co.uk) on behalf on the National Institute of Health Research (NIHR) NIHR CRN Good Clinical Practice Reference Resource DISCLAIMER Although this GCP Resource contains information of a legal nature, it has been developed for information and education purposes only and does not constitute legal advice or opinions as to the current operative laws, regulations, or guidelines of any jurisdiction. In addition, because new standards are issued on a continuing basis, this GCP Resource is not an exhaustive source of all current applicable laws, regulations, and guidelines relating to non-interventional studies. While reasonable efforts have been made to assure the accuracy and completeness of the information provided, researchers and other individuals should check with the applicable National Competent Authorities and/or Research Ethics Committees before starting research activities. Copyright Information UK Statutory Instruments and Acts: Crown Copyright material is reproduced with the permission of the Controller of HMSO and the Queen’s Printer for Scotland. This information is licensed under the terms of the Open Government Licence (link) European Regulations, Directives and Guidelines: European Community Copyright material is reproduced with the permission of the European Commission. Version 3, May 2011 © NIHR CRN 2010 - 2011 3 NIHR CRN Good Clinical Practice Reference Resource Foreword The following document contains links to GCP-related articles, references, documents and websites and is aimed to serve as a resource to help develop and further your knowledge about Good Clinical Practice (GCP).
    [Show full text]
  • Good Clinical Practice (GCP)
    Good Clinical Practice (GCP) Angela Del Vecchio 18 maggio 2018 1 Dichiarazione di trasparenza/interessi* Le opinioni espresse in questa presentazione sono personali e non impegnano in alcun modo l’AIFA Da 0 a Interessi nell’industria farmaceutica NO Attualmente oltre 3 anni precedenti 3 anni precedenti INTERESSI DIRETTI: 1.1 Impiego per una società: Ruolo esecutivo in una x obbligatorio società farmaceutica 1.2 Impiego per una società: Ruolo guida nello sviluppo x obbligatorio di un prodotto farmaceutico 1.3 Impiego per una società: altre attività x facoltativo 2. Consulenza per una società x facoltativo 3. Consulente strategico per una società x facoltativo 4. Interessi finanziari x facoltativo 5. Titolarità di un brevetto x facoltativo INTERESSI INDIRETTI: 6. Sperimentatore principale x facoltativo 7. Sperimentatore x facoltativo 8. Sovvenzioni o altri fondi finanziari x facoltativo 9. Interessi Familiari x facoltativo * Angela Del Vecchio, secondo il regolamento sul Conflitto di Interessi approvato dal CdA AIFA in data 25.03.2015 e pubblicato sulla Gazzetta Ufficiale del 15.05.2015 in accordo con la policy EMA /626261/2014 sulla gestione del conflitto di interessi dei membri dei Comitati Scientifici e degli esperti. N.B. <Per questo intervento non ricevo alcun compenso> DEFINITION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the partecipation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected and that the clinical trial data are credible. INTERNATIONAL CONFERENCE ON HARMONISATION (ICH) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry of Europe, Japan and the US to discuss scientific and technical aspects of drug registration.
    [Show full text]
  • E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry
    E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2018 Procedural OMB Control No. 0910-0843 Expiration Date 09/30/2020 See additional PRA statement in section 9 of this guidance. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 885-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 Email: [email protected] http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2018 Procedural Contains Nonbinding Recommendations TABLE OF CONTENTS INTRODUCTION ...............................................................................................................
    [Show full text]
  • Good Clinical Practice: from Review to Application
    Good Clinical Practice: From Review to Application by: Rebecca York, Clinical Research Associate, IMARC Research As clinical research professionals, we often hear phrases like, “It’s in the regs!” Or, “It’s GCP!” At times, it may seem as though by classifying our actions as “GCP,” we wave a magic wand that ensures regulatory compliance. But what is GCP, and what does it mean to be GCP compliant? In order to take “good” to “great,” it is important understand the conceptual framework that supports good clinical practice and be able to apply that understanding in daily research practice. Introduction and Literature Review Good clinical practice is an attitude of credible excellence in research that provides a standard for clinical study design, Good clinical practice is more implementation, conduct and analysis. Good clinical practice is more than any one document; rather, it is a collective than any one document; rather, compilation of many thoughts, ideas and learning moments it is a collective compilation spanning the globe over. Furthermore, good clinical practice of many thoughts, ideas and is a mindset that is absolutely essential to the protection of learning moments spanning the patients’ rights and the assurance of data integrity. globe over. A comprehensive representation of the development of good clinical practice can be found in a literature review of the Declaration of Helsinki, the Common Rule, the Belmont Report, the World Health Organization Guidelines for GCP, the International Conference on Harmonization, and the FDA Code of Federal Regulations. This is by far not a complete list of the regulatory documents that comprise GCP, but rather an excellent launch pad into the conceptual framework within which research professionals must comply.
    [Show full text]
  • Good Clinical Practice in Clinical Trials Kapil Verma* Amity Institute of Forensic Sciences (AIFS), Amity University, Uttar Pradesh, India
    Clin l of ica Verma, J Clin Trials 2013, 3:1 a l T n r r i u a o l s DOI: 10.4172/2167-0870.1000128 J Journal of Clinical Trials ISSN: 2167-0870 Review Article Open Access Base of a Research: Good Clinical Practice in Clinical Trials Kapil Verma* Amity Institute of Forensic Sciences (AIFS), Amity University, Uttar Pradesh, India Abstract This article illustrates the importance of Good Clinical Practice (GCP), defines and outlines the goals of GCP, presents a historical perspective on GCP and Outlines FDA regulations relating to GCP. Ongoing research shows that whether conducting research involving a new drug, a behavioral intervention, or an interview/survey, Good Clinical Practice (GCP) provides investigators and their study teams with the tools to protect human subjects and collect quality data. In this article, the author will define GCP, explain the benefits of following GCP for all types of human research and clinical trial studies, and provide some resources to assist investigators in implementing the tenets of GCP for their own research studies. This article reviews the impact of Good Clinical Practice (GCP) on clinical trials. GCP is likely to follow the International Conference on Harmonization of GCP guidelines in many aspects. GCP will enforce tighter guidelines on ethical aspects of a clinical study. Higher standards will be required in terms of comprehensive documentation for the clinical protocol, record keeping, training, and facilities including computers. Quality assurance and inspections will ensure that these standards are achieved. The additional requirements of GCP are discussed and any advantage to the study subject.
    [Show full text]
  • Safety Monitoring and Reporting for Clinical Trials in Europe
    Safety monitoring and reporting for clinical trials in Europe Ingrid Wallenbeck, Head Clinical Trials Unit, Medical Products Agency, Uppsala Sweden Overview of Safety work • Data from preclinical studies - what is expected and tolerable? • During administration to volunteers or patients - safety measures in study protocol - report whatever is reported or observed - serious- non-serious - serious and expected or serious and unexpected? • Reference Safety Information - Product specific - Investigator Brochure or SPC Obligations to report During Clinical Studies – Serious Unexpected Serious Adverse Reactions (SUSARs) – Annual SafetyReport (ASR) – New format: Development Safety Update Reports (DSUR For Marketed Prodcts – Periodic Safety Update Reports (PSUR) Study protocol work To be considered: – Protocol structure according to ICH E6 section 6 – Safety measures in protocol (ICH E6 section 6.8) – Special safety considerations (product related) – Need for data monitoring board – Safety reporting time after treatment termination To be reported All Adverse Reactions including – Severity (mild, moderate, severe) – Seriousness (serious, non-serious) – Relatedness (unrelated, possibly related, probably related) Definition of Adverse Reaction "Any untoward or unfavorable medical occurrence in a clinical research study participant, including any abnormal sign (e.g. abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participants’ involvement in the research, whether or not considered related to participation
    [Show full text]
  • Classification and Analysis of the GCP Inspection Findings of GCP Inspections Conducted at the Request of the CHMP (Inspection Reports to EMA 2000-2012)
    01 December 2014 INS/GCP/46309/2012 Compliance and Inspections Classification and analysis of the GCP inspection findings of GCP inspections conducted at the request of the CHMP (Inspection reports to EMA 2000-2012) 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5505 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. TABLE OF CONTENTS 1. GLOSSARY .............................................................................................................................................................. 3 2. INTRODUCTION .................................................................................................................................................... 4 3. SCOPE AND AIMS .................................................................................................................................................. 6 4. METHOD .................................................................................................................................................................. 6 4.1. INFORMATION ABOUT FINDINGS ........................................................................................................................... 6 4.2. INFORMATION ABOUT THE APPLICATIONS ............................................................................................................ 7 4.3. INFORMATION ABOUT
    [Show full text]
  • Good Clinical Practice & Good Clinical Practice & Medical
    Good Clinical Practice & Medical Record Documentation Hanne Baekgaard Larsen & Terri Halverson Objectives: • Understand the history behind and define some key components of “Good Clinical Practice” • Identify barriers to data extraction and reporting • Explore some possible approaches for making data abstraction more efficient and accurate 2 Good Clinical Practice & Medical Record Documentation The history Rigshospitalet, Copenhagen, Denmark Hanne Baekgaard Larsen RN, MSc, p h. d. s tu den t 3 Pure Food and Drug Act of 1906 • The agricultural society and traditional medicine. • The Industrial Revolution. • The “Poison Squad” and the novel “The Jungle”. 4 1937 The Elixir Sulfanilamide Incident. • Sulfanilamide to treat Streptococcal infections • Diethylene glycol = antifreeze = dea dly poison (but pleasant taste) • 107 people died • Federal Food, Drug, and Cosmetic Act of 1938. 5 1941 U.S. vs. Dotterweich. • Buffalo Pharmacal Company charged with shipping adulterated and misbranded ppgroducts e.g. digitalis tablets • Responsible individuals can be held personally accountable for the quality of the products manufactured by their company. 6 1960 The Thalidomide Incident • Used, in Europe, to treat sleep disorder and morning sickness in pregnant women. • In Germany alone 5000 babies were born with birth defects. • 1962 Drug Amendment: safety requirements for testing on human subjects, information on experimental drugs, adverse effects during clinical trials, listing side effects as well as benefits. 7 1947 The Nuremberg Code • Voluntary consent
    [Show full text]
  • ICH E9 Guideline on Statistical Principles for Clinical Trials
    INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E9 Current Step 4 version dated 5 February 1998 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA. E9 Document History New First Codification History Date Codification November 2005 E9 Approval by the Steering Committee under Step 2 and 16 E9 release for public consultation. January 1997 Current Step 4 version E9 Approval by the Steering Committee under Step 4 and 5 E9 recommendation for adoption to the three ICH February regulatory bodies. 1998 STATISTICAL PRINCIPLES FOR CLINICAL TRIALS ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 5 February 1998, this guideline is recommended for adoption to the three regulatory parties to ICH TABLE OF CONTENTS I. INTRODUCTION ...............................................................................................1 1.1 Background and Purpose .....................................................................................1 1.2 Scope and Direction..............................................................................................2 II. CONSIDERATIONS FOR OVERALL
    [Show full text]
  • ICH E6: Good Clinical Practice: Consolidated Guideline
    _____________________________________________________________ 3CC1a ■ GOOD CLINICAL PRACTICE*) Guideline Title Good Clinical Practice*) Legislative basis Directive 75/318/EEC as amended Date of first adoption July 1990 This version July 1996 Date of entry into January 1997 force Status Last revised 1996 Previous titles/other ICH E6: Good Clinical Practice: Consolidated guideline, references CPMP/ICH/135/95 Additional Notes This note for guidance concerns the application of Part 4, sections B and C of the Annex to Directive 75/318/EEC as amended with a view to the granting of a marketing authorisation for a medicinal product. It established the principles for standards of Good Clinical Practice both within the European Community and within the ICH regions. It replaces the previous 1990 guideline entitled Good Clinical Practice for Trials on Medicinal Products in the European Community (III/3976/88), adopted May 1990. CONTENTS INTRODUCTION 1. GLOSSARY 2. THE PRINCIPLES OF ICH GCP 3. INSTITUTIONAL REVIEW BOARD / INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 4. INVESTIGATOR 5. SPONSOR 6. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S) 7. INVESTIGATOR’S BROCHURE 8. ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 3 _____________________________________________________________ 3CC1a ■ GOOD CLINICAL PRACTICE*) INTRODUCTION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. The objective of this ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions.
    [Show full text]
  • Good Clinical Practice - a Guide to Archiving
    Good Clinical Practice - A Guide to Archiving 2nd Edition July 2014 Foreword One of the fundamental requirements of the principles of Good Clinical Practice (GCP) is the need to ensure the integrity and secure retention of clinical trial documents for a period of time determined by legal, regulatory and business requirements. Essential Documents serve to demonstrate the compliance of the investigator, sponsor, and monitor with the standards of GCP and with all applicable regulatory requirements. The first version of this guidance was published in 2007. The second edition has been produced to reflect changes in regulations since then, and to address feedback received on the first version. The guidance and advice contained within this document are consistent with the requirements of EU Commission Clinical Trial Directive 2001/20/EC and supporting Directives, UK SI 1928:2006, US 21CFR312 and ICH GCP Guidelines. Acknowledgements The following members of the Scientific Archivists Group participated in the Working Party that produced this updated version of the guidance. Without their expertise and commitment, it could not have been produced. Chris Jones, March 2014 Jennifer Barnwell Liz Hooper Russell Joyce Mary Paul Eldin Rammell Cara Lax-Williams Chris Jones © Copyright 2014 by Scientific Archivists Group Limited All rights reserved. This book or any portion thereof may not be reproduced or used in any manner whatsoever without the express written permission of the publisher except for the use of brief quotations in a book review or scholarly journal. First Printing: 2007 Second Printing: 2014 ISBN 978-0-9557659-3-3 Scientific Archivists Group Limited Registered Office Berkeley Townsend, Hunter House, 150 Hutton Road, Shenfield, Essex, CM15 8NL, UK www.sagroup.org.uk Contents 1 SCOPE ..............................................................................................
    [Show full text]
  • An Overview of Good Clinical Practice (GCP)
    An Overview of Good Clinical Practice (GCP) Daniel Redline, BA, CCRP Director, Clinical/Pre-Clinical Affairs February 17, 2011 Objectives Explain the origin and purpose of Good Clinical Practice (GCP). Describe the International Conference on Harmonization’s Guideline for Good Clinical Practice (ICH GCP). Discuss the ICH GCP Guideline and its importance in conducting safe, ethical, and sound clinical research Objectives (Continued) Discuss the rationale for the development and implementation of Standard Operating Procedures (SOPs). Good Clinical Practice Is a standard for designing, conducting, performing, monitoring, auditing, recording, analyzing, and reporting clinical trials Provides assurance that data and reported results are credible and accurate and that the rights and confidentiality of subjects are protected Elements of Good Clinical Practice Federal Regulations Other government “The letter of the regulations law” State and local Regulatory Agency laws Guidelines Sponsor, site, ICH GCP Guideline ERC/EC/IRB, SOPs “The spirit of the Practice Acts and law” Licensure ISO 14155: 1 and 2 Standards of Care Relationship Between GCP Elements ICH (International Conference on Harmonization) Guideline for GCP Provide a unified standard for the European Union (EU), Japan, and the United States to facilitate the mutual acceptance of the clinical data by the regulatory authorities in these jurisdictions ICH Guideline for GCP The ICH Guideline is an effort to define GCP and to create and provide a unified standard for designing,
    [Show full text]